Skip to search formSkip to main contentSkip to account menu

regorafenib

Known as: 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide, Regorafenibum 
An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular… 
National Institutes of Health

Related topics

Related topics

5 relations
NCIt Antineoplastic Agent TerminologyStivargaregorafenib 40 MG Oral Tablet [Stivarga]

Broader (2)

Phenylurea CompoundsPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A Pilot Study of Apatinib as Third‐Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer
2018
2018
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma
Background Although sorafenib-regorafenib sequential therapy improves the prognosis of patients with hepatocellular carcinoma… 
2017
2017
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
The SHARP study in 2007 [1] and the Asia Pacific study in 2008 [2] led to the worldwide approval of sorafenib as the standard… 
2017
2017
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy
2017
2017
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.
5506Background: ICON6 is a three-arm double-blind, placebo-controlled phase 3 trial of cediranib in platinum-sensitive relapsed… 
2015
2015
Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer
Background Regorafenib induces distinct radiological changes that represent its anti-angiogenic effect. However, clinical… 
Review
2014
Review
2014
Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer.
Review
2014
Review
2014
Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.
Review
2013
Review
2013
Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis
Regorafenib is a novel multikinase inhibitor approved for use in metastatic colorectal cancer (mCRC) and locally advanced… 
2012
2012
Antiangiogenesis therapy in the treatment of metastatic colorectal cancer
The process of new blood vessel formation, or angiogenesis, has become an important target for therapeutic intervention in many… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)